Astellas Pharma Enters Into Joint Research Agreement With Sony

(RTTNews) - Sony Corp. (SON.L, SNE) and Astellas Pharma Inc. (ALPMY, ALPMY) have entered into a research agreement to discover an Antibody-Drug Conjugate platform in oncology based on Sony's polymeric material, KIRAVIA 2 Backbone. The companies will jointly develop and optimize a new ADC platform using the KIRAVIA Backbone as a linker. Also, Astellas will conduct non-clinical trials of development candidates.

KIRAVIA Backbone is created using the organic polymer technology cultivated in KIRAVIA Dyes, which Sony independently developed. It features a high degree of freedom in design.

The companies jointly began exploratory research of new linker technology aimed at creating a new ADC platform in July 2022. Also, the companies have agreed to continue discussions on expanding research partnerships to create new value by combining Sony's technology with Astellas' pharmaceutical capabilities.

For More Such Health News, visit rttnews.com.